A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Healthy Clinical Trial

Official title:

A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01419925
• Other study ID #: BVX-005
• Status: Completed
• Phase: Phase 2
• First received: August 17, 2011
• Last updated: May 12, 2014
• Start date: August 2011
• Est. completion date: January 2012

Study information

• Verified date: May 2014
• Source: BiondVax Pharmaceuticals ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

"Multimeric-001" (M-001) has been recently developed, containing conserved, common linear influenza epitopes that activate both cellular and humoral arms of the immune system against a wide variety of influenza A and B strains. Apart from its direct action, M-001 is an attractive candidate for priming immune responses to seasonal influenza vaccine in the elderly population. The current clinical study was designed to assess M-001's standalone and priming action in subjects over 65 years old.

This is a second Phase II study comprising 120 participants. Eligible subjects were randomized to receive to receive either two sequential non-adjuvanted or a single non-adjuvanted or a single adjuvanted intramuscular injection of 500 mcg M-001 (treatment), or one placebo (saline) injection, before receiving the TIV.

Description:

This was a two-center, randomized, placebo-controlled study. 120 subjects were randomized 1:1:1:1 into four groups to receive either two sequential non-adjuvanted or a single non-adjuvanted or a single adjuvanted intramuscular injection of 500 mcg M-001 (treatment), or one placebo (saline) injection, before receiving the TIV. Due to visual differences between placebo and treatment the study was partially blinded. Hemagglutinin inhibition (HAI) was evaluated at baseline and 3 weeks after standard trivalent inactivated influenza vaccine (TIV) vaccination as a measure of M-001's efficacy. Cell mediated immune (CMI) responses were also evaluated in some of the subjects who received non-adjuvanted and adjuvanted M-001 vaccinations. The subjects were monitored for safety throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Males and females at the age of at least 65 years old

• Eligible to receive the standard seasonal influenza vaccine according to the MOH guidelines.

• Subjects who provide written informed consent to participate in the study.

• Subjects able to adhere to the visit schedule and protocol requirements and are available to complete the study.

• Haematology, chemistry and urinalysis values with no clinical significance or do not reflect a medical condition which, according to the physician's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study.

• Male subjects must agree to use a condom during the full term of the study period (including follow up) if female partner is not using an acceptable contraceptive method.

• Subjects who are seronegative to at least one of the strains included in the seasonal vaccine against influenza for 2011- 2012

Exclusion Criteria:

• Known history of significant medical disorder which, in the investigator's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study.

• Subjects with known Guillain Barré Syndrome in the past.

• Subjects who have been immunized with anti-influenza vaccine or infected by influenza virus within eight months prior to the screening visit.

• Known hypersensitivity associated with previous influenza vaccination.

• Use of an influenza antiviral medication within 4 weeks of vaccination.

• Known hypersensitivity and/or allergy to any drug or vaccine.

• Known hypersensitivity to egg proteins (eggs or egg products), chicken proteins, or any of the components of the commercial vaccine (e.g., formaldehyde, and octoxinol 9 (Triton X-100) and neomycin).

• Persons deficient in producing antibodies, whether due to genetic defect, immunodeficiency disease, or immunosuppressive therapy.

• History of any bleeding disorder or subjects with thrombocytopenia (since bleeding may occur following an intramuscular administration to these subjects).

• Any clinically significant abnormality upon physical examination or in the clinical laboratory tests at screening visit which, according to the physician's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study.

• Positive serology for HIV, HCV antibody or HBsAg.

• Any acute medical situation (e.g. acute infection, ongoing flu symptoms) with or without fever within 48 hours of vaccination, which is considered significant by the Investigator.

• Subjects who participated in another interventional clinical study within 30 days prior to first dose

• Subjects who are non-cooperative or unwilling to sign consent form.

Related Conditions & MeSH terms

• Healthy
• Influenza
• Influenza, Human

Intervention

Biological:
• Two Multimeric-001 administrations followed by TIV
Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
• One administration of Multimeric-001 followed by TIV
One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
• One administration of adjuvanted M-001 followed by TIV
One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
• One administration of placebo followed by TIV
One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)

Locations

Country	Name	City	State
Israel	Hadassah medical center	Jerusalem

Sponsors (1)

Lead Sponsor	Collaborator
BiondVax Pharmaceuticals ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events	Number of Participants with Adverse Events as a Measure of Safety and Tolerability were similar (not statistically significant) in the experimental and control group; Number of Participants with Adverse Events possible/probably related to the study drug in each treatment group: Group A: Twice M-001 - 9 AEs Group B: Once M-001 - 5 AEs Group C: Once Alum-M-001 - 13 AEs Group D: Placebo - 7 AEs	63 days
Secondary	Immunity induced by priming and boosting, measured by HAI	Hemagglutination Inhibition (HAI) test for anti influenza antibodies to TIV strains revealed an elevated proportion of participants achieving seroconversion in the groups primed with M-001 and boosted with TIV, as compared to participants given TIV alone. The viruses contained in the TIV were A/California/7/09, A/Perth/16/09 or B/Brisbane/60/08 . Enhanced Seroconversion and GMT post immunization were found in the experimental group primed with either adjuvanted or non adjuvanted M-001. Note that the superior HAI responses were demonstrated for both seasonal (H3N2 and B strain) and pandemic strains (swine H1N1 strain that is contained in the TIV).	21 days after boost immunization with TIV
Secondary	Cellular immunity	Intracellular staining followed by FACS analysis of CD4/CD8 lymphocytes secreting IFN gamma showed elevated proportions of CD4+ cells secreting IFN gamma following exposure of PBMC from subjects immunized with M-001 to influenza antigens and to M-001. Note that the test was performed before boosting with TIV and hence demonstrates the cross immunity offered by immunization with M-001 alone and suggests a CD4+ mediated mechanism of action for M-001 as a universal primer.	21 days after M-001 immunization